Using a smartphone app to improve care for cancer patients undergoing chemotherapy
Differential Effects of a Telemonitoring Platform in the Development of Chemotherapy-Associated Toxicity: A Randomised Trial
This study is testing whether a smartphone app can help improve the experience and quality of life for adults with cancer who are getting chemotherapy compared to regular in-person care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universidad Nacional Andres Bello Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Santiago and 1 other locations) |
| Trial ID | NCT06077123 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the effectiveness of a telemonitoring platform, specifically the Contigo application, in enhancing patient satisfaction and quality of life among adult cancer patients receiving chemotherapy. Participants will be randomly assigned to either use the Contigo app, which monitors chemotherapy toxicity and provides educational content, or receive standard in-person care. The study will involve patients diagnosed with various solid tumors who are starting outpatient chemotherapy at designated healthcare centers in Santiago, Chile. Data on patient experiences and toxicity symptoms will be collected and analyzed to determine the app's impact compared to traditional care.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old, proficient in Spanish, with a confirmed diagnosis of specific solid tumors, and scheduled for outpatient chemotherapy.
Not a fit: Patients undergoing concurrent radiotherapy or those with sensory or cognitive impairments that prevent app usage will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the quality of life and satisfaction with care for cancer patients undergoing chemotherapy.
How similar studies have performed: Other studies have shown promising results with telemonitoring approaches in cancer care, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (\>18 years) * Histologically confirmed diagnosis of lung, gastric, gallbladder, colon, breast, or cervical carcinoma in any of its forms and stages * Initiating an outpatient curative intent chemotherapy regimen within the facilities of UC-Christus Health Network or Hospital Sotero del Río during the months of November 2023 to July 2024 * Proficient in the Spanish language * Possess a smartphone, regardless of the native operating system (iOS® or Android®) Exclusion Criteria: * Individuals undergoing concomitant radiotherapy * Those with any form of sensory impairment hindering the use of the application * Those with cognitive impairment or psychiatric pathology preventing the use of the application * Those who do not wish to participate in the study
Where this trial is running
Santiago and 1 other locations
- Centro del Cáncer, Pontificia Universidad Católica de Chile — Santiago, Chile (Recruiting)
- Complejo Asistencial Dr. Sotero del Río — Santiago, Chile (Not_yet_recruiting)
Study contacts
- Principal investigator: Manuel Espinoza, PhD — Pontificia Universidad Catolica de Chile
- Study coordinator: Felipe Martinez, MD, MSc
- Email: felipe.martinez.l@unab.cl
- Phone: +56 9 99690953
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.